Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GOLGA4_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GOLGA4_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GOLGA4_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GOLGA4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/GOLGA4_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GOLGA4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/GOLGA4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GOLGA4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/GOLGA4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GOLGA4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GOLGA4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006195122 | Skin | cSCC | establishment of protein localization to plasma membrane | 30/4864 | 60/18723 | 5.67e-05 | 5.67e-04 | 30 |
GO:004300115 | Skin | cSCC | Golgi to plasma membrane protein transport | 22/4864 | 40/18723 | 8.93e-05 | 8.37e-04 | 22 |
GO:0032535111 | Skin | cSCC | regulation of cellular component size | 131/4864 | 383/18723 | 1.89e-04 | 1.59e-03 | 131 |
GO:000155824 | Skin | cSCC | regulation of cell growth | 140/4864 | 414/18723 | 2.07e-04 | 1.72e-03 | 140 |
GO:001072016 | Skin | cSCC | positive regulation of cell development | 105/4864 | 298/18723 | 2.30e-04 | 1.89e-03 | 105 |
GO:003134622 | Skin | cSCC | positive regulation of cell projection organization | 120/4864 | 353/18723 | 4.49e-04 | 3.44e-03 | 120 |
GO:005076913 | Skin | cSCC | positive regulation of neurogenesis | 80/4864 | 225/18723 | 8.85e-04 | 6.07e-03 | 80 |
GO:003030722 | Skin | cSCC | positive regulation of cell growth | 61/4864 | 166/18723 | 1.39e-03 | 8.78e-03 | 61 |
GO:005076722 | Skin | cSCC | regulation of neurogenesis | 118/4864 | 364/18723 | 3.32e-03 | 1.81e-02 | 118 |
GO:001097522 | Skin | cSCC | regulation of neuron projection development | 141/4864 | 445/18723 | 3.72e-03 | 1.99e-02 | 141 |
GO:006156422 | Skin | cSCC | axon development | 146/4864 | 467/18723 | 5.50e-03 | 2.73e-02 | 146 |
GO:00507729 | Skin | cSCC | positive regulation of axonogenesis | 31/4864 | 79/18723 | 6.63e-03 | 3.23e-02 | 31 |
GO:006056023 | Skin | cSCC | developmental growth involved in morphogenesis | 78/4864 | 234/18723 | 7.08e-03 | 3.40e-02 | 78 |
GO:004592719 | Skin | cSCC | positive regulation of growth | 85/4864 | 259/18723 | 8.03e-03 | 3.73e-02 | 85 |
GO:199013823 | Skin | cSCC | neuron projection extension | 59/4864 | 172/18723 | 9.20e-03 | 4.20e-02 | 59 |
GO:005196213 | Skin | cSCC | positive regulation of nervous system development | 88/4864 | 272/18723 | 1.07e-02 | 4.66e-02 | 88 |
GO:00325355 | Stomach | GC | regulation of cellular component size | 44/1159 | 383/18723 | 5.66e-05 | 1.31e-03 | 44 |
GO:003253511 | Stomach | CAG with IM | regulation of cellular component size | 41/1050 | 383/18723 | 5.55e-05 | 1.38e-03 | 41 |
GO:00726596 | Stomach | CAG with IM | protein localization to plasma membrane | 27/1050 | 284/18723 | 5.25e-03 | 4.19e-02 | 27 |
GO:003253521 | Stomach | CSG | regulation of cellular component size | 41/1034 | 383/18723 | 3.94e-05 | 1.04e-03 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GOLGA4 | SNV | Missense_Mutation | | c.3932A>G | p.Asn1311Ser | p.N1311S | Q13439 | protein_coding | tolerated(0.75) | benign(0.001) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
GOLGA4 | SNV | Missense_Mutation | | c.3722N>A | p.Ile1241Asn | p.I1241N | Q13439 | protein_coding | tolerated(0.55) | benign(0.037) | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
GOLGA4 | SNV | Missense_Mutation | rs768808136 | c.296N>A | p.Arg99Gln | p.R99Q | Q13439 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GOLGA4 | SNV | Missense_Mutation | rs764030527 | c.4237N>A | p.Glu1413Lys | p.E1413K | Q13439 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GOLGA4 | SNV | Missense_Mutation | rs750023676 | c.6565N>A | p.Glu2189Lys | p.E2189K | Q13439 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GOLGA4 | SNV | Missense_Mutation | novel | c.431G>A | p.Ser144Asn | p.S144N | Q13439 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AO-A1KP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
GOLGA4 | SNV | Missense_Mutation | | c.1411N>A | p.Glu471Lys | p.E471K | Q13439 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
GOLGA4 | SNV | Missense_Mutation | | c.6097N>A | p.Glu2033Lys | p.E2033K | Q13439 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
GOLGA4 | SNV | Missense_Mutation | | c.1885N>A | p.Val629Ile | p.V629I | Q13439 | protein_coding | tolerated(0.36) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GOLGA4 | SNV | Missense_Mutation | | c.1372N>A | p.Glu458Lys | p.E458K | Q13439 | protein_coding | deleterious(0.02) | probably_damaging(0.922) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |